G
Grove Biopharma
Developing drugs to treat serious diseases
About Grove Biopharma
Grove Biopharma is a preclinical biotechnology startup based in Chicago, operating at the intersection of precision polymers, protein engineering, and medicinal chemistry. The company focuses on therapeutic targeting of protein-protein interactions using its proprietary Precision Linked Proteomimetic chemistry platform. This platform, developed by co-founder Professor Nathan Gianneschi at Northwestern University, enables the creation of customizable, synthetic, protein-scale molecules. Grove Biopharma is a member of the Portal biotech incubator space, which supports its mission to reshape drug discovery. The company serves clients in the pharmaceutical and biotechnology sectors, aiming to advance drug modalities that address complex intracellular interactions. Grove Biopharma generates revenue through partnerships and collaborations with other biotech firms and research institutions. The team includes experts like Brandon Nelson, Ph.D., a Principal Scientist in Chemistry, who brings extensive experience in oncology and small molecule drug discovery from his tenure at AbbVie. Keywords: biotechnology, drug discovery, proteomimetics, protein interactions, precision polymers, protein engineering, medicinal chemistry, preclinical, Chicago, incubator.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Chicago, United States
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 90.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Biotech and Pharma, AI Drug Discovery, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Grove Biopharma.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2025 | $30M | $120M | Portal Innovations · Mansueto Office · InVivium Capital · Walder Ventures | ↗ |
| CONVERTIBLEEquity / VC | Jun 2022 | $2.5M | — | DeepWork Capital | — |
Growth signals
Latest recorded traffic for Grove Biopharma is 1.3K monthly website visits, down 27.8% over the last three months. Grove Biopharma's team grew 52.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Portal Innovations
Skydeck Capital
Joseph Mansueto
Walder Ventures
Series A6 investors entered at this stage
DeepWork Capital
DCVC Bio- MOMansueto Office
- ICInVivium Capital
Gradient
Eli Lilly
Other known investors1 additional known investor
Northwestern University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Grove Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Grove Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







